| __timestamp | BioCryst Pharmaceuticals, Inc. | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 122000 | 21226345 |
| Thursday, January 1, 2015 | 1896000 | 139626 |
| Friday, January 1, 2016 | 2699000 | 93831530 |
| Sunday, January 1, 2017 | 1702000 | 79419009 |
| Monday, January 1, 2018 | 471000 | 368673 |
| Tuesday, January 1, 2019 | 4101000 | 477121 |
| Wednesday, January 1, 2020 | 1676000 | 1895029 |
| Friday, January 1, 2021 | 7264000 | 8034589 |
| Saturday, January 1, 2022 | 6594000 | 20443000 |
| Sunday, January 1, 2023 | 4661000 | 33745000 |
In pursuit of knowledge
In the competitive world of biotechnology, understanding cost structures is crucial. Over the past decade, Intra-Cellular Therapies, Inc. and BioCryst Pharmaceuticals, Inc. have shown distinct trajectories in their cost of revenue. From 2014 to 2023, Intra-Cellular Therapies experienced a dramatic increase, peaking in 2016 with costs nearly 40 times higher than BioCryst's. This surge reflects their aggressive investment in research and development. Meanwhile, BioCryst's costs remained relatively stable, with a notable spike in 2021, suggesting strategic shifts or increased production. By 2023, Intra-Cellular Therapies' costs were approximately 7 times higher than BioCryst's, indicating a sustained commitment to innovation. These trends highlight the differing strategies of these biotech firms, offering insights into their operational priorities and market positioning.
Analyzing Cost of Revenue: Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Merck & Co., Inc. and Intra-Cellular Therapies, Inc.
Cost of Revenue Comparison: AstraZeneca PLC vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
Comparing Cost of Revenue Efficiency: Teva Pharmaceutical Industries Limited vs BioCryst Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and BioCryst Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Jazz Pharmaceuticals plc vs BioCryst Pharmaceuticals, Inc.
Cytokinetics, Incorporated vs BioCryst Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Alkermes plc and BioCryst Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down Geron Corporation and BioCryst Pharmaceuticals, Inc.'s Expenses